The role of prostaglandin E2 in renal cell cancer development: future implications for prognosis and therapy

2014 ◽  
Vol 10 (14) ◽  
pp. 2177-2187 ◽  
Author(s):  
Katarzyna Kaminska ◽  
Cezary Szczylik ◽  
Fei Lian ◽  
Anna M Czarnecka
Keyword(s):  
Prostaglandin E2 ◽  
Renal Cell Cancer ◽  
Renal Cell ◽  
Cell Cancer ◽  
Cancer Development

scholarly journals Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review

2006 ◽  
Vol 17 (8) ◽  
pp. 1185-1196 ◽  
Author(s):  
P. Schöffski ◽  
H. Dumez ◽  
P. Clement ◽  
A. Hoeben ◽  
H. Prenen ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitors ◽  
Renal Cell Cancer ◽  
Renal Cell ◽  
Kinase Inhibitors ◽  
Cell Cancer ◽  
Advanced Renal Cell Cancer

International renal-cell-cancer study. VI. The role of medical and family history

1996 ◽  
Vol 66 (6) ◽  
pp. 723-726 ◽  
Author(s):  
Brigitte Schlehofer ◽  
Wolfgang Pommer ◽  
Anders Mellemgaard ◽  
John H. Stewart ◽  
Margaret McCredie ◽  
...  
Keyword(s):  
Family History ◽  
Renal Cell Cancer ◽  
Renal Cell ◽  
Cell Cancer ◽  
Cancer Study

Immunotherapy for Advanced Renal Cell Cancer: The Role of Radical Nephrectomy

1990 ◽  
Vol 18 (2) ◽  
pp. 42-45 ◽  
Author(s):  
Arie Belldegrun ◽  
Alec S. Kroo ◽  
Bernard Bochner ◽  
Robert Figlin ◽  
Jean B. deKernion
Keyword(s):  
Renal Cell Cancer ◽  
Renal Cell ◽  
Radical Nephrectomy ◽  
Cell Cancer ◽  
Advanced Renal Cell Cancer

The patient with renal cell cancer

2015 ◽  
Author(s):  
Tim Eisen
Keyword(s):  
Tyrosine Kinase ◽  
Cell Carcinoma ◽  
Tyrosine Kinase Inhibitors ◽  
Renal Cancer ◽  
Renal Cell Cancer ◽  
Renal Cell ◽  
Kinase Inhibitors ◽  
Kinase Inhibitor ◽  
Cell Cancer

Renal cancer is the commonest malignancy of the kidney and worldwide, accounts for between 2% and 3% of the total cancer burden. The mainstay of curative treatment remains surgery. There have been significant advances in surgical technique, the most important ones being nephron-sparing surgery and laparoscopic nephrectomy. The medical treatment of advanced renal cell cancer has only improved markedly in the last decade with the development of antiangiogenic tyrosine-kinase inhibitors, inhibitors of mammalian target of rapamycin, and a diminished role for immunotherapy.Tyrosine-kinase inhibitor therapy results in reduction of tumour volume in around three-quarters of patients and doubles progression-free survival, but treatment is not curative. The management of side effects in patients on maintenance tyrosine-kinase inhibitors has improved in the last 3 years, although still presents difficulties which have to be actively considered.The molecular biology of renal cell carcinoma is better understood than for the majority of solid tumours. The commonest form of renal cancer, clear-cell carcinoma of the kidney, is strongly associated with mutations in the von Hippel–Lindau gene and more recently with chromatin-remodelling genes such as PBRM1. These genetic abnormalities lead to a loss of control of angiogenesis and uncontrolled proliferation of tumour cells. There is a very wide spectrum of tumour behaviour from the extremely indolent to the terribly aggressive. It is not currently known what accounts for this disparity in tumour behaviour.A number of outstanding questions are being addressed in scientific and clinical studies such as a clearer understanding of prognostic and predictive molecular biomarkers, the role of adjuvant therapy, the role of surgery in the presence of metastatic disease, how best to use our existing agents, and investigation of novel targets and therapeutic agents, especially novel immunotherapies.

Interleukin 10 polymorphism may influence renal cell cancer development

2003 ◽  
Vol 2 (6) ◽  
pp. 133
Author(s):  
Erik G Havranek ◽  
Mike Whelan ◽  
Joseph Whelan ◽  
Angus Dalgleish ◽  
Chris Anderson ◽  
...  
Keyword(s):  
Renal Cell Cancer ◽  
Renal Cell ◽  
Cell Cancer ◽  
Interleukin 10 ◽  
Cancer Development
Sign in / Sign up

Export Citation Format

Share Document